University of California San Francisco

Publications

Selected Publications
  1. Abstract C025: Identification of cell-cell signaling programs across the tumor-tumor microenvironment ecosystem and associated with clinical status in neoadjuvant osimertinib treated patient samples revealed by spatial profiling.
    2024 | UCSF Research Profile
  2. The crystal structure of the protein kinase HIPK2 reveals a unique architecture of its CMGC-insert region.
    2019 | PubMed
  3. Drug development against the hippo pathway in mesothelioma.
    2017 | PubMed
  4. Analysis of lung tumor initiation and progression in transgenic mice for Cre-inducible overexpression of Cul4A gene.
    2015 | PubMed
  5. Hematein, a casein kinase II inhibitor, inhibits lung cancer tumor growth in a murine xenograft model.
    2013 | PubMed
  6. The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma.
    2011 | PubMed
  7. Epigenetic alteration of the Wnt inhibitory factor-1 promoter occurs early in the carcinogenesis of Barrett's esophagus.
    2007 | PubMed
  8. Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma.
    2006 | PubMed
  9. Wnt signaling in lung cancer.
    2005 | PubMed
  10. Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts.
    2004 | PubMed
  11. Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin.
    2003 | PubMed
  12. Identification of differentially expressed nucleolar TGF-beta1 target (DENTT) in human lung cancer cells that is a new member of the TSPY/SET/NAP-1 superfamily.
    2001 | PubMed
  13. Differential regulation of protease and extracellular matrix protein expression by transforming growth factor-beta 1 in non-small cell lung cancer cells and normal human bronchial epithelial cells.
    1997 | PubMed
  14. P1.07.40 Detection of ctDNA Prior to Neoadjuvant Osimertinib Treatment Correlates With Decreased EFS in EGFR-Mutated NSCLC.
    2025 | UCSF Research Profile
  15. Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.
    2024 | PubMed
  16. The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer.
    2018 | PubMed
  17. YAP1 regulates ABCG2 and cancer cell side population in human lung cancer cells.
    2017 | PubMed
  18. Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells.
    2015 | PubMed
  19. Inhibition of CK2α down-regulates Notch1 signalling in lung cancer cells.
    2013 | PubMed
  20. Procaine and procainamide inhibit the Wnt canonical pathway by promoter demethylation of WIF-1 in lung cancer cells.
    2009 | PubMed
  21. Roles of secreted frizzled-related proteins in cancer.
    2007 | PubMed
  22. The role of Wnt signaling in cancer and stem cells.
    2005 | PubMed
  23. Dickkopf-1 antagonizes Wnt signaling independent of beta-catenin in human mesothelioma.
    2004 | PubMed
  24. Activity of the suppressor of cytokine signaling-3 promoter in human non-small-cell lung cancer.
    2004 | PubMed
  25. A comparison analysis of anti-tumor efficacy of adenoviral gene replacement therapy (p14ARF and p16INK4A) in human mesothelioma cells.
    2003 | PubMed
  26. Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells.
    2000 | PubMed
  27. Frameshift mutation in codon 176 of the p53 gene in rat esophageal epithelial cells transformed by benzo[a]pyrene dihydrodiol.
    1995 | PubMed
  28. An international, multicenter, prospective randomized trial of adjuvant chemotherapy for stage Ia-IIa non-small cell lung cancer identified as high-risk by a 14-gene molecular assay.
    2025 | UCSF Research Profile
  29. Inhibition of cyclin-dependent kinase 7 down-regulates yes-associated protein expression in mesothelioma cells.
    2019 | PubMed
  30. YAP regulates PD-L1 expression in human NSCLC cells.
    2017 | PubMed
  31. Knockdown of Cul4A increases chemosensitivity to gemcitabine through upregulation of TGFBI in lung cancer cells.
    2015 | PubMed
  32. Lung tumourigenesis in a conditional Cul4A transgenic mouse model.
    2014 | PubMed
  33. Transgenic mice for cre-inducible overexpression of the Cul4A gene.
    2011 | PubMed
  34. Nasopharyngeal carcinoma--review of the molecular mechanisms of tumorigenesis.
    2008 | PubMed
  35. An antagonist of dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth.
    2007 | PubMed
  36. Wnt signaling in stem cells and non-small-cell lung cancer.
    2005 | PubMed
  37. Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells.
    2004 | PubMed
  38. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer.
    2003 | PubMed
  39. A multicenter evaluation of assays for detection of SV40 DNA and results in masked mesothelioma specimens.
    2001 | PubMed
  40. Reduction in transforming growth factor-beta type II receptor in mouse lung carcinogenesis.
    1998 | PubMed
  41. Parental bias of Ki-ras oncogenes detected in lung tumors from mouse hybrids.
    1992 | PubMed
  42. 8P Precision medicine drug testing platform to guide the treatment of EML4-ALK fusion lung cancers.
    2024 | UCSF Research Profile
  43. Cucurbitacin E inhibits the Yes‑associated protein signaling pathway and suppresses brain metastasis of human non‑small cell lung cancer in a murine model.
    2019 | PubMed
  44. DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesothelioma.
    2017 | PubMed
  45. Genistein Suppresses Growth of Human Uterine Sarcoma Cell Lines via Multiple Mechanisms.
    2015 | PubMed
  46. Coumestrol from the national cancer Institute's natural product library is a novel inhibitor of protein kinase CK2.
    2013 | PubMed
  47. Adenovirus-mediated SOCS3 gene transfer inhibits the growth and enhances the radiosensitivity of human non-small cell lung cancer cells.
    2010 | PubMed
  48. Targeting the Wnt signaling pathway with dishevelled and cisplatin synergistically suppresses mesothelioma cell growth.
    2007 | PubMed
  49. Wnt signaling activation and WIF-1 silencing in nasopharyngeal cancer cell lines.
    2006 | PubMed
  50. Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations.
    2005 | PubMed
  51. Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer.
    2004 | PubMed
  52. Genomic alterations in human mesothelioma including high resolution mapping of common regions of DNA loss in chromosome arm 6q.
    2003 | PubMed
  53. Prostaglandin E2 and vasoactive intestinal peptide increase vascular endothelial cell growth factor mRNAs in lung cancer cells.
    2001 | PubMed
  54. Effects of transforming growth factor-beta 1 and phorbol ester on PAI-1 and PA genes in human lung cells.
    1997 | PubMed
  55. Never Fear, the Robot Is Here: Robotic Resection for a Giant Thymoma.
    2025 | PubMed
  56. A novel isoform of Homeodomain-interacting protein kinase-2 promotes YAP/TEAD transcriptional activity in NSCLC cells.
    2021 | PubMed
  57. Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma.
    2018 | PubMed
  58. YAP promotes erlotinib resistance in human non-small cell lung cancer cells.
    2016 | PubMed
  59. CK2α, over-expressed in human malignant pleural mesothelioma, regulates the Hedgehog signaling pathway in mesothelioma cells.
    2014 | PubMed
  60. Inhibition of CK2α down-regulates Hedgehog/Gli signaling leading to a reduction of a stem-like side population in human lung cancer cells.
    2012 | PubMed
  61. Promoter demethylation of WIF-1 by epigallocatechin-3-gallate in lung cancer cells.
    2009 | PubMed
  62. Wnt inhibitory factor-1 gene transfer inhibits melanoma cell growth.
    2007 | PubMed
  63. Wnt2 as a new therapeutic target in malignant pleural mesothelioma.
    2005 | PubMed
  64. Cloning and characterization of the promoter of human Wnt inhibitory factor-1.
    2004 | PubMed
  65. A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells.
    2004 | PubMed
  66. Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides.
    2002 | PubMed
  67. ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients.
    2000 | PubMed
  68. Tumor multiplicity, DNA adducts and K-ras mutation pattern of 5-methylchrysene in strain A/J mouse lung.
    1994 | PubMed
  69. Letter: Commentary: Trans-Sternal Multilevel Corpectomy for Cervicothoracic Renal Cell Metastasis: 2-Dimensional Operative Video.
    2024 | PubMed
  70. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
    2019 | PubMed
  71. Hippo pathway in lung development.
    2017 | PubMed
  72. Cul4A overexpression associated with Gli1 expression in malignant pleural mesothelioma.
    2015 | PubMed
  73. CUL4A induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression.
    2013 | PubMed
  74. Cul4A is an oncogene in malignant pleural mesothelioma.
    2011 | PubMed
  75. Evaluation of a chemical library of small-molecule Dishevelled antagonists that suppress tumor growth by down-regulating T-cell factor-mediated transcription.
    2008 | PubMed
  76. Stathmin is overexpressed in malignant mesothelioma.
    2007 | PubMed
  77. Efficacy of Wnt-1 monoclonal antibody in sarcoma cells.
    2005 | PubMed
  78. An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth.
    2004 | PubMed
  79. Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression.
    2003 | PubMed
  80. Indomethacin reduces lung adenoma number in A/J mice.
    2001 | PubMed
  81. Identification of early growth response gene-1 (Egr-1) as a phorbol myristate acetate-induced gene in lung cancer cells by differential mRNA display.
    1997 | PubMed
  82. Activation of protooncogenes in mouse lung tumors.
    1991 | PubMed
  83. Outpatient opioid use after minimally invasive surgery for lung cancer: a Surveillance, Epidemiology, and End Results-Medicare cohort study.
    2025 | PubMed
  84. Precision medicine-based platform to guide the treatment of EML4-ALK driven lung cancers and other NSCLC in real time.
    2024 | UCSF Research Profile
  85. Cul4A Modulates Invasion and Metastasis of Lung Cancer Through Regulation of ANXA10.
    2019 | PubMed
  86. Targeting YAP in malignant pleural mesothelioma.
    2017 | PubMed
  87. PR-Set7 is Degraded in a Conditional Cul4A Transgenic Mouse Model of Lung Cancer.
    2015 | PubMed
  88. Frizzled-8 receptor is activated by the Wnt-2 ligand in non-small cell lung cancer.
    2013 | PubMed
  89. Functional polymorphism of the CK2alpha intronless gene plays oncogenic roles in lung cancer.
    2010 | PubMed
  90. Inhibition of Wnt-2 and galectin-3 synergistically destabilizes beta-catenin and induces apoptosis in human colorectal cancer cells.
    2007 | PubMed
  91. Wnt-1 signal as a potential cancer therapeutic target.
    2006 | PubMed
  92. Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in beta-catenin-deficient human mesothelioma cells.
    2005 | PubMed
  93. Inhibition of Wnt-1 signaling induces apoptosis in beta-catenin-deficient mesothelioma cells.
    2004 | PubMed
  94. Cloning and characterization of a functional promoter of the human SOCS-3 gene.
    2003 | PubMed
  95. Stage II (N1) lung cancer.
    2001 | PubMed
  96. Carcinogenicity, DNA adduct formation and K-ras activation by 7H-dibenzo[c,g]carbazole in strain A/J mouse lung.
    1996 | PubMed
  97. Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial.
    2025 | PubMed
  98. The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC).
    2020 | PubMed
  99. Inhibition of yes-associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model.
    2018 | PubMed
  100. Knockdown of cullin 4A inhibits growth and increases chemosensitivity in lung cancer cells.
    2016 | PubMed
  101. An alternative way to initiate Notch1 signaling in non-small cell lung cancer.
    2014 | PubMed
  102. The expression of Dishevelled-3 and glutamine metabolism in malignant pleural mesothelioma.
    2012 | PubMed
  103. Identification of hematein as a novel inhibitor of protein kinase CK2 from a natural product library.
    2009 | PubMed
  104. Wnt inhibitory factor inhibits lung cancer cell growth.
    2007 | PubMed
  105. Inhibition of Wnt16 in human acute lymphoblastoid leukemia cells containing the t(1;19) translocation induces apoptosis.
    2005 | PubMed
  106. Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma.
    2004 | PubMed
  107. Future directions: oncolytic viruses.
    2004 | PubMed
  108. p14(ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53.
    2001 | PubMed
  109. Transforming growth factor-beta expression in mouse lung carcinogenesis.
    1998 | PubMed
  110. Allele-specific activation and expression of the K-ras gene in hybrid mouse lung tumors induced by chemical carcinogens.
    1994 | PubMed